Biogen completes USD85M acquisition of Alcyone Therapeutics to advance CNS drug delivery technology

USA—Biogen has finalized its acquisition of Alcyone Therapeutics, a US-based company specializing in central nervous system drug delivery solutions.

The biotechnology giant paid USD85 million upfront to secure the deal, which was first announced through a definitive agreement in September 2025.

The acquisition centers on Alcyone’s innovative ThecaFlex DRx drug delivery system, an experimental implantable device that represents a significant advancement in treating neurological disorders.

This intrathecal catheter offers patients a more convenient alternative to repeated lumbar punctures, which are typically required for chronic intrathecal administration of medications.

The device works by providing direct access to cerebrospinal fluid, allowing for continuous therapeutic infusion without the need for frequent invasive procedures.

Currently, the ThecaFlex DRx system remains under investigation in clinical studies.

Researchers are evaluating its effectiveness for administering nusinersen, the active ingredient in Spinraza, which treats spinal muscular atrophy.

The device has already achieved important regulatory milestones, including a CE Mark in Europe that allows for clinical use.

Additionally, the US Food and Drug Administration granted both an investigational device exemption for clinical studies and a breakthrough device designation, recognizing its potential to address unmet medical needs.

Lisa Shafer, who leads CMC development and product delivery solutions at Biogen, emphasized the strategic importance of this acquisition.

She explained that the ThecaFlex DRx system enables Biogen to combine its biopharmaceutical innovation with cutting-edge medical device technology.

This integration strengthens the company’s existing portfolio while expanding its capabilities in developing pioneering delivery methods for therapeutic treatments.

Shafer further highlighted that this transaction demonstrates Biogen’s ongoing dedication to advancing drug delivery solutions.

The company believes such innovations can significantly improve patient experiences while making Biogen’s therapies more accessible to those who need them.

With the acquisition complete, Biogen now plans to launch the ThecaFlex DRx system for use with Spinraza in early 2028.

This timeline depends on successfully completing ongoing clinical trials and obtaining necessary regulatory approvals.

Biogen maintains global rights to develop, manufacture, and commercialize Spinraza through a licensing agreement with Ionis Pharmaceuticals, positioning the company to fully integrate this new delivery technology into its treatment offerings for spinal muscular atrophy patients worldwide.